- Home
- MYN vs EBS Comparison
MYN vs EBS Comparison
Compare MYN & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYN | EBS |
|---|---|---|
| Founded | 1992 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.0M | 312.8M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | MYN | EBS |
|---|---|---|
| Price | $8.86 | $6.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 330.9K | ★ 990.8K |
| Earning Date | 01-01-0001 | 10-28-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.68 | $4.36 |
| 52 Week High | $10.26 | $14.06 |
Technical Indicators
Market Signals| Indicator | MYN | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 30.85 | 51.73 |
| Support Level | N/A | $5.50 |
| Resistance Level | $10.03 | $6.60 |
| Average True Range (ATR) | 0.14 | 0.28 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 29.37 | 40.57 |
Price Performance
Historical ComparisonAbout MYN Blackrock MuniYield New York Quality Fund Inc.
BLACKROCK MUNIYIELD N Y QUALITY FD INC is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.